S-1 plus docetaxel and cisplatin as an induction chemotherapy for advanced oral squamous cell carcinoma:A clinical observation
10.16571/j.cnki.1008-8199.2016.10.013
- VernacularTitle:替吉奥联合多西他赛和顺铂诱导化疗晚期口腔鳞状细胞癌的临床观察
- Author:
Xu DING
;
Huaiqi LI
;
Xiaomeng SONG
;
Yunong WU
;
Heming WU
- Publication Type:Journal Article
- Keywords:
S-1;
Docetaxel;
Cisplatin;
Oral squamous cell carcinoma;
Induction chemotherapy
- From:
Journal of Medical Postgraduates
2016;29(10):1067-1070
- CountryChina
- Language:Chinese
-
Abstract:
Objective There are quite a few chemotherapeutic adjuvants for the treatment of advanced oral squamous cell carcinoma, but all have their adverse effects. This study was to evaluate the efficacy and adverse effects of the induction chemotherapy of S?1 plus docetaxel and cisplatin in the treatment of advanced oral squamous cell carcinoma. Methods Totally, 84 patients with advanced oral squamous cell carcinoma were randomly divided into an observation and a control group of equal number, the former trea?ted with S?1 plus docetaxel and cisplatin and the latter with 5?fluorouracil, docetaxel and cisplatinand, both for two cycles ( 1 cycle =21 d) . Then the effects and adverse events were evaluated and compared between the two groups of patients. Results No statistically significant differences were observed in the response rate between the observation and control groups of patients (76.19% vs 73.81%, P>0.05). The incidence rates of adverse events, such as nausea and vomiting (66.67% vs 88.10%, P<0.05) and phlebitis (0 vs 19.05%, P<0.05) , were remarkably lower in the former than in the latter group. Conclusion S?1 plus docetaxel and cisplatin is a reli?able induction chemotherapy with few adverse effects in the treatment of advanced oral squamous cell carcinoma.
